Tafamidis (Vyndaqel®) is indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||30/03/2020|
|Rapid review completed||07/04/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical and cost effectiveness of tafamidis compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||29/04/2020|
|Pre-submission consultation with Applicant||18/05/2020|
|Full submission received from Applicant||01/07/2020|
|Preliminary review sent to Applicant||18/08/2020|
|NCPE assessment recommenced||10/09/2020|
|Factual accuracy sent to Applicant||11/09/2020|
|NCPE assessment recommenced||18/09/2020|
|NCPE assessment completed||25/09/2020|
|NCPE assessment outcome||The NCPE recommends that tafamidis not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.